MYC and neoplasm: Together with the c-Myc inhibition observed in Figure 7A, these findings indicate that the metformin-alpelisib combination synergistically targets both oncogenic signaling networks and stemness regulatory pathways, providing an integrated mechanistic basis for its enhanced anti-tumor effects.